Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
June 10, 2024 8:58 AM EDT
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $310.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "Todays announcement for positive phase III data for mRNA-1083, its combination flu + COVID-19 vaccine candidate, supports our outlook. Combination vaccines have the... More
June 10, 2024 6:52 AM EDT
Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $95.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "This morning MRNA announced that its Ph3 trial of mRNA-1083 (combo vaccine against influenza and COVID-19) has met its primary endpoints (LINK). We view this as an incremental positive for the stock as it could help bolster the tail of the COVID franchise, but we await further insight on the regulatory path. The ongoing Ph3 trial evaluated mRNA-1083 in two separate age groups of ~4,000 adults each. One consisted of adults 65 years and older,... More
June 10, 2024 6:52 AM EDT
Jefferies analyst Michael Yee reiterated a Buy rating and $180.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "Phase III data from MRNA's Covid+Flu combo vaccine today generally looks in-line with expectations and shows superior level of antibody titers in... More
